Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer by Colin R. Lindsay, Pavlina Spiliopoulou, Ashita Waterston

Get full text

Testicular cancer: improving outcomes with national quality performance indicators by Ashita Waterston, Jeff White, Mark A Baxter, Graham MacDonald, Jahangeer Malik, Alistair Law, Åsa Dahle-Smith, Walter Mmeka, Roland Donat, Cj Shukla, John Connor, Colin Houston

Get full text

Comprehensive Characterization of the Vascular Effects of Cisplatin-Based Chemotherapy in Patients With Testicular Cancer by Alan C. Cameron, MBChB, PhD, Kelly McMahon, BSc, Mark Hall, MBChB, Karla B. Neves, PhD, Francisco J. Rios, PhD, Augusto C. Montezano, PhD, Paul Welsh, PhD, Ashita Waterston, MBChB, PhD, Jeff White, MBChB, DM, Patrick B. Mark, MBChB, PhD, Rhian M. Touyz, MBBCh, PhD, Ninian N. Lang, MBChB, PhD

Get full text

3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT by Timothy Iveson, Kathleen A Boyd, Rachel S Kerr, Jose Robles-Zurita, Mark P Saunders, Andrew H Briggs, Jim Cassidy, Niels Henrik Hollander, Josep Tabernero, Andrew Haydon, Bengt Glimelius, Andrea Harkin, Karen Allan, John McQueen, Sarah Pearson, Ashita Waterston, Louise Medley, Charles Wilson, Richard Ellis, Sharadah Essapen, Amandeep S Dhadda, Mark Harrison, Stephen Falk, Sherif Raouf, Charlotte Rees, Rene K Olesen, David Propper, John Bridgewater, Ashraf Azzabi, David Farrugia, Andrew Webb, David Cunningham, Tamas Hickish, Andrew Weaver, Simon Gollins, Harpreet Wasan, James Paul

Get full text